Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9400-0.1200 (-5.83%)
At close: 04:00PM EST
1.9300 -0.01 (-0.52%)
After hours: 06:30PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0600
Open2.0700
Bid1.9300 x 900
Ask1.9800 x 1300
Day's Range1.9030 - 2.0750
52 Week Range1.9030 - 9.6700
Volume857,086
Avg. Volume603,240
Market Cap82.944M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-2.1120
Earnings DateSep 07, 2021 - Sep 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.78
  • TipRanks

    These 2 Penny Stocks Could Surge Over 400%, Says Wells Fargo

    The rapid rise in the stock market has investors in buying mood. Rising stocks are offering the best returns in today’s climate of ultra-low interest rates, and if investors choose carefully, they can find stocks that are poised to beat the increasing rate of inflation as well. And that will bring us to penny stocks. For any investor seeking the best returns, the ‘pennies’ are a natural place to look. Traditionally stocks sold at prices lower than one dollar, penny stocks these days are consider

  • GlobeNewswire

    AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

    With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC’s preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-

  • GlobeNewswire

    AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting

    - Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) -GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the presentation of additional analyses and conclu

Advertisement
Advertisement